NAC reduces flu and bronchitis

[Guest guest]

Jules,

Why wouldn't EVERYONE take NAC every day???

NAC is known to be VERY safe, even if taken randomly every day. There is no

significant toxicity, even at high doses.

NAC has been shown to significantly reduce mortality when taken as a

supplement in HIV at Stanford University at the Herzerbergs' Lab.

Further, NAC, taken at 1200 mg per day has been shown in a six month study

of 262 adults to significantly reduce the incidence and severity of the flu

by about 54 percent. See study below. (1)

600 mg of NAC per day has been shown to reduce the number of sick days from

bronchitis. (2)

It is a valuable SAFE supplement that ANYONE, positive or negative should

consider taking every day. If you are trying to support immune function, you

might consider doing what I, and HIV-negative person do........take 500 mg

twice per day, based on the flu study.

It also has significant potential as an anti-aging supplement by supporting

the body's antioxidant mechanisms.

General recommendations NOT to take dietary supplements without providing

supporting science as to why they are not safe or useful are not in our best

interest. Please provide data when you make a recommendation.

Mooney

www.medibolics.com

www.michaelmooney.net

Message: 13

Date: Wed, 7 Dec 2005 05:24:15 EST

From: JuLev@...

Subject: Re: The liver and supplements

I understand that when people have serious acute liver damage that treatment

may be required & NAC & other supplements have been used successfully. This

however is a different situation than using the same supplement for therapy

when

acute liver damage has not occurred. Just because NAC may have demonstrated

benefit in acute liver damage does not translate into that it provides

significant benefit to a liver infected with HCV & inflammation.

Jules

****************************************************

1. Attenuation of influenza-like symptomatology and improvement of

cell-mediated immunity

with long-term N-acetylcysteine treatment. S. De Flora, C. Grassi, L.

Carati. ¿ERS

Journal Ltd 1997. Eur Respir J 1997; 10: 1535-1541.

ABSTRACT: N-acetylcysteine (NAC), an analogue and precursor of reduced

glutathione,

has been in clinical use for more than 30 yrs as a mucolytic drug. It has

also been proposed for and/or used in the therapy and/or prevention of

several

respiratory diseases and of diseases involving an oxidative stress, in

general. The

objective of the present study was to evaluate the effect of long-term

treatment

with NAC on influenza and influenza-like episodes.

A total of 262 subjects of both sexes (78% ?65 yrs, and 62% suffering from

nonrespiratory

chronic degenerative diseases) were enrolled in a randomized, doubleblind

trial involving 20 Italian Centres. They were randomized to receive either

placebo or NAC tablets (600 mg) twice daily for 6 months. Patients suffering

from

chronic respiratory diseases were not eligible, to avoid possible

confounding by an

effect of NAC on respiratory symptoms.

NAC treatment was well tolerated and resulted in a significant decrease in

the

frequency of influenza-like episodes, severity, and length of time confined

to bed.

Both local and systemic symptoms were sharply and significantly reduced in

the

NAC group. Frequency of seroconversion towards A/H1N1 Singapore 6/86

influenza

virus was similar in the two groups, but only 25% of virus-infected subjects

under

NAC treatment developed a symptomatic form, versus 79% in the placebo group.

Evaluation of cell-mediated immunity showed a progressive, significant shift

from

anergy to normoergy following NAC treatment.

Administration of N-acetylcysteine during the winter, thus, appears to

provide

a significant attenuation of influenza and influenza-like episodes,

especially in elderly

high-risk individuals. N-acetylcysteine did not prevent A/H1N1 virus

influenza

infection but significantly reduced the incidence of clinically apparent

disease.

2. Parr, G.D. and A. Huitson, Oral Fabrol (oral N-acetyl-cysteine) in

chronic bronchitis. Br J Dis Chest, 1987. 81(4): p. 341-8.